Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Successful pleurodesis with OK-432 in preterm infants with persistent pleural effusion

  • Kim, Jeong-Eun (Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine) ;
  • Lee, Chul (Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine) ;
  • Park, Kook-In (Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine) ;
  • Park, Min-Soo (Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine) ;
  • NamGung, Ran (Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine) ;
  • Park, In-Kyu (Department of Thoracic and Cardiovascular Surgery, Severance Children's Hospital, Yonsei University College of Medicine)
  • Received : 2011.09.06
  • Accepted : 2011.11.28
  • Published : 2012.05.15
Download PDF
⟨ Previous Next ⟩

Abstract

OK-432 (picibanil) is an inactivated preparation of $Streptococcus$ pyogenes that causes pleurodesis by inducing a strong inflammatory response. Intrapleural instillation of OK-432 has recently been used to successfully treat neonatal and fetal chylothorax. Here we report a trial of intrapleural instillation of OK-432 in two preterm infants who were born with hydrops fetalis and massive bilateral pleural effusion. Both cases showed persistent pleural effusion, refractory to conservative treatment, up to postnatal days 26 and 46, respectively. An average of 80 to 140 mL of pleural fluid was drained daily. In case 1, the infant was treated with OK-432 during the fetal period at gestation 28 weeks and 4 days of gestation, but showed recurrence of pleural effusion and progressed into hydrops. Within two to three days after OK-432 injection, the amount of pleural fluid drainage was dramatically decreased and there was no reaccumulation. We did not observe any side effects related to OK-432 injection. We suggest that OK-432 should be considered as a therapeutic option in infants who have persistent pleural effusion for more than four weeks, with the expectation of the early removal of the chest tube and a good outcome.

Keywords

References

  1. Al-Tawil K, Ahmed G, Al-Hathal M, Al-Jarallah Y, Campbell N. Congenital chylothorax. Am J Perinatol 2000;17:121-6. https://doi.org/10.1055/s-2000-9281
  2. Caserio S, Gallego C, Martin P, Moral MT, Pallas CR, Galindo A. Congenital chylothorax: from foetal life to adolescence. Acta Paediatr 2010;99:1571-7. https://doi.org/10.1111/j.1651-2227.2010.01884.x
  3. Ergaz Z, Bar-Oz B, Yatsiv I, Arad I. Congenital chylothorax: clinical course and prognostic significance. Pediatr Pulmonol 2009;44:806-11. https://doi.org/10.1002/ppul.21070
  4. Cleveland K, Zook D, Harvey K, Woods RK. Massive chylothorax in small babies. J Pediatr Surg 2009;44:546-50. https://doi.org/10.1016/j.jpedsurg.2008.08.008
  5. Katanyuwong P, Dearani J, Driscoll D. The role of pleurodesis in the management of chylous pleural effusion after surgery for congenital heart disease. Pediatr Cardiol 2009;30:1112-6. https://doi.org/10.1007/s00246-009-9515-1
  6. Okazaki T, Iwatani S, Yanai T, Kobayashi H, Kato Y, Marusasa T, et al. Treatment of lymphangioma in children: our experience of 128 cases. J Pediatr Surg 2007;42:386-9. https://doi.org/10.1016/j.jpedsurg.2006.10.012
  7. Park JS, Kim JK, Kim CB. OK-432 (picibanil) chemical pleurodesis for the treatment of persistent chylothorax after esophagectomy. J Korean Surg Soc 2001;61:105-9.
  8. Nygaard U, Sundberg K, Nielsen HS, Hertel S, Jorgensen C. New treatment of early fetal chylothorax. Obstet Gynecol 2007;109:1088-92. https://doi.org/10.1097/01.AOG.0000259907.91973.69
  9. Chen M, Shih JC, Wang BT, Chen CP, Yu CL. Fetal OK-432 pleurodesis: complete or incomplete? Ultrasound Obstet Gynecol 2005;26:791-3. https://doi.org/10.1002/uog.2634
  10. Yim GW, Kwon JY, Park YW, Kim YH. Successful antenatal treatment of early fetal chylothorax with OK-432 pleurodesis. Korean J Obstet Gynecol 2009;52:752-8.
  11. Kim GJ, Lee ES. Cesarean delivery with postnatal high-frequency ventilation immediately after thoracocentesis for a fetus with intractable congenital chylothorax. Korean J Obstet Gynecol 2011;54:99-102. https://doi.org/10.5468/KJOG.2011.54.2.99
  12. Matsukuma E, Aoki Y, Sakai M, Kawamoto N, Watanabe H, Iwagaki S, et al. Treatment with OK-432 for persistent congenital chylothorax in newborn infants resistant to octreotide. J Pediatr Surg 2009;44:e37-9.
  13. Rocha G. Pleural effusions in the neonate. Curr Opin Pulm Med 2007; 13:305-11. https://doi.org/10.1097/MCP.0b013e3281214459
  14. Beghetti M, La Scala G, Belli D, Bugmann P, Kalangos A, Le Coultre C. Etiology and management of pediatric chylothorax. J Pediatr 2000;136:653-8. https://doi.org/10.1067/mpd.2000.104287
  15. Buttiker V, Fanconi S, Burger R. Chylothorax in children: guidelines for diagnosis and management. Chest 1999;116:682-7. https://doi.org/10.1378/chest.116.3.682
  16. Das A, Shah PS. Octreotide for the treatment of chylothorax in neonates. Cochrane Database Syst Rev 2010;(9):CD006388.
  17. Sahin Y, Aydin D. Congenital chylothorax treated with octreotide. Indian J Pediatr 2005;72:885-8. https://doi.org/10.1007/BF02731124
  18. Wasmuth-Pietzuch A, Hansmann M, Bartmann P, Heep A. Congenital chylothorax: lymphopenia and high risk of neonatal infections. Acta Paediatr 2004;93:220-4. https://doi.org/10.1111/j.1651-2227.2004.tb00710.x
  19. Cowie RV, Stone PR, Parry E, Jensen EC, Gunn AJ, Bennet L. Acute behavioral effects of intrapleural OK-432 (Picibanil) administration in preterm fetal sheep. Fetal Diagn Ther 2009;25:304-13. https://doi.org/10.1159/000235876
  20. Bennet L, Cowie RV, Stone PR, Barrett R, Naylor AS, Blood AB, et al. The neural and vascular effects of killed Su-Streptococcus pyogenes (OK- 432) in preterm fetal sheep. Am J Physiol Regul Integr Comp Physiol 2010;299:R664-72. https://doi.org/10.1152/ajpregu.00116.2010

Cited by

  1. Congenital Chylothorax: Diagnosis Problems vol.8, pp.2, 2012, https://doi.org/10.5005/jp-journals-10009-1357
  2. Congenital Chylothorax: Diagnosis Problems vol.8, pp.2, 2012, https://doi.org/10.5005/jp-journals-10009-1357
  3. Pleural disease in infants and children: management updates vol.5, pp.1, 2016, https://doi.org/10.1007/s13665-016-0134-z
  4. The effects of aqueous extract of babassu (Orbignya phalerata) on the pleura and lung parenchyma in rats vol.31, pp.4, 2016, https://doi.org/10.1590/s0102-865020160040000004
  5. Successful management of extremely high‐output refractory congenital chylothorax with chemical pleurodesis using 4% povidone–iodine and propranolol: a case report vol.6, pp.4, 2012, https://doi.org/10.1002/ccr3.1449
  6. Successful Management of Fetal Hydrothorax associated with Hydrops vol.12, pp.2, 2012, https://doi.org/10.5005/jp-journals-10009-1564
  7. Congenital Chylothorax: Common and Uncommon Findings in an Infant with Chylous Effusions vol.38, pp.6, 2019, https://doi.org/10.1891/0730-0832.38.6.357
  8. Successful Treatment of Intractable Chylothorax with Povidone-Iodine Pleurodesis in Extremely Preterm Infant vol.32, pp.1, 2012, https://doi.org/10.14734/pn.2021.32.1.31
  9. Chylothorax in the neonate—A stepwise approach algorithm vol.56, pp.10, 2012, https://doi.org/10.1002/ppul.25601